NCT03810651
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +19 more
- Locations
-
- Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
Clinical trial condition
Wilms Tumor
Explore clinical trials studying Wilms Tumor. Study availability and eligibility vary by location and protocol.
57 public trials
14 recruiting studies
Wilms Tumor trial results
NCT05384821
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more
- Locations
-
- CHU Amiens Picardie Amiens, France
- CHU de Besancon Besançon, France
- CHRU de Bordeaux Hôpital des Enfants Bordeaux, France
- CHU GRENOBLE ALPES - Hôpital COUPLE ENFANT Grenoble, France
NCT07148050
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +40 more
- Locations
-
- Seattle Children's Hospital Seattle, Washington, United States
NCT06198296
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +38 more
- Locations
-
- Houston Methodist Hospital Houston, Texas, United States
Active, not recruiting
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03210714
- Conditions
- Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +74 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, not recruiting
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03698994
- Conditions
- Advanced Malignant Solid Neoplasm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, +83 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States
Active, not recruiting
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592
- Conditions
- Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Arkansas Children's Hospital Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim Anaheim, California, United States
Active, not recruiting
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ependymoma, Female Urogenital Diseases, +85 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
NCT03155620
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, +99 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Phoenix Childrens Hospital Phoenix, Arizona, United States
Active, not recruiting
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652
- Conditions
- Advanced Malignant Solid Neoplasm, Central Nervous System Neoplasms, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +82 more
- Locations
-
- Children's Hospital of Alabama Birmingham, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Banner Children's at Desert Mesa, Arizona, United States
- Banner University Medical Center - Tucson Tucson, Arizona, United States